Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Resverasin is a multi-ingredient dietary supplement developed and marketed by NutriMed Group, a pharmaceutical company based in Ukraine. The product is designed to support cardiovascular health and provide systemic antioxidant protection. Its formulation includes resveratrol, red wine extract, and grape seed extract. Resveratrol, the primary active component, is a natural polyphenol that acts as a potent antioxidant and a positive allosteric modulator of NAD-dependent protein deacetylase sirtuin-1 (SIRT1). Activation of SIRT1 is associated with improved metabolic function, cellular longevity, and vascular protection. The additional extracts from red wine and grape seeds provide a spectrum of polyphenols and oligomeric proanthocyanidins that enhance endothelial function, inhibit lipid peroxidation, and support healthy blood pressure. Resverasin is typically indicated for individuals seeking to mitigate age-related cardiovascular risks and oxidative stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Resverasin.